CU24692B1 - Proceso industrial para la preparación de estetrol de alta pureza - Google Patents
Proceso industrial para la preparación de estetrol de alta purezaInfo
- Publication number
- CU24692B1 CU24692B1 CU2022000013A CU20220013A CU24692B1 CU 24692 B1 CU24692 B1 CU 24692B1 CU 2022000013 A CU2022000013 A CU 2022000013A CU 20220013 A CU20220013 A CU 20220013A CU 24692 B1 CU24692 B1 CU 24692B1
- Authority
- CU
- Cuba
- Prior art keywords
- estetrol
- preparation
- high purity
- industrial process
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a la preparación de estetrol de fórmula (I), derivados del mismo, protegidos en las posiciones 3,15α, 16α, 17β de fórmula general (III), y derivados 3-hidroxi del mismo protegidos en las posiciones 15α, 16α, 17β de fórmula general (IV), y a los productos intermedios de fórmulas generales (III) y (IV) aplicados en el proceso, que permite su producción en alta pureza y puede llevarse a cabo a través de intermediarios con propiedades ventajosas (por ejemplo, cristalización, purificación, aislabilidad, rendimiento).</p> <p>ESPACIO PARA FÓRMULA</p> <p> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1900315A HU231240B1 (hu) | 2019-09-03 | 2019-09-03 | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| PCT/IB2020/058148 WO2021044302A1 (en) | 2019-09-03 | 2020-09-02 | Industrial process for the preparation of high purity estetrol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20220013A7 CU20220013A7 (es) | 2022-10-11 |
| CU24692B1 true CU24692B1 (es) | 2024-01-10 |
Family
ID=89992977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2022000013A CU24692B1 (es) | 2019-09-03 | 2020-09-02 | Proceso industrial para la preparación de estetrol de alta pureza |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US11633406B2 (es) |
| EP (1) | EP3877395B1 (es) |
| JP (1) | JP7265087B2 (es) |
| KR (1) | KR102871606B1 (es) |
| CN (1) | CN114302889B (es) |
| AU (1) | AU2020343497B2 (es) |
| CA (1) | CA3147815C (es) |
| CL (1) | CL2022000492A1 (es) |
| CO (1) | CO2022003769A2 (es) |
| CU (1) | CU24692B1 (es) |
| DK (1) | DK3877395T3 (es) |
| EC (1) | ECSP22022403A (es) |
| ES (1) | ES2855923T3 (es) |
| FI (1) | FI3877395T3 (es) |
| GE (1) | GEP20247626B (es) |
| HR (1) | HRP20230230T1 (es) |
| HU (2) | HU231240B1 (es) |
| IL (1) | IL290973B2 (es) |
| JO (1) | JOP20220041A1 (es) |
| LT (1) | LT3877395T (es) |
| MA (1) | MA54200B1 (es) |
| MD (1) | MD3877395T2 (es) |
| MX (1) | MX2022002603A (es) |
| MY (1) | MY206905A (es) |
| NZ (1) | NZ786568A (es) |
| PE (1) | PE20221418A1 (es) |
| PH (1) | PH12022550388A1 (es) |
| PL (1) | PL3877395T3 (es) |
| PT (1) | PT3877395T (es) |
| RS (1) | RS63966B1 (es) |
| SI (1) | SI3877395T1 (es) |
| WO (1) | WO2021044302A1 (es) |
| ZA (1) | ZA202203557B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022005359A2 (pt) * | 2019-09-27 | 2022-07-19 | Ind Chimica Srl | Processo de preparação de (15a,16a,17ss)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol(estetrol) e intermediários do referido processo |
| DE112021008305T5 (de) * | 2021-10-01 | 2024-07-25 | Industriale Chimica S.R.L. | VERFAHREN ZUR HERSTELLUNG VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) UND ESTETROL-MONOHYDRAT |
| HUP2500316A1 (en) * | 2023-02-02 | 2025-11-28 | Ind Chimica Srl | Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) monohydrate |
| CN117088928B (zh) * | 2023-08-16 | 2025-09-09 | 湖北共同甾体药物研究院有限公司 | 用于制备高纯度雌四醇的工艺 |
| CN119569803B (zh) * | 2023-09-05 | 2025-09-16 | 秦皇岛紫竹药业有限公司 | 一种制备高纯度雌四醇的方法 |
| HUP2400151A1 (hu) | 2024-02-28 | 2025-09-28 | Richter Gedeon Nyrt | Ösztetrol-monohidrát kristályosítási eljárás |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE350041T1 (de) | 2001-05-18 | 2007-01-15 | Pantarhei Bioscience Bv | Pharmaceutishe zusammensetzung für die hormonersatztherapie |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| EP1390042B1 (en) | 2001-05-23 | 2007-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| WO2002094278A1 (en) | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| ATE347365T1 (de) | 2001-11-15 | 2006-12-15 | Pantarhei Bioscience Bv | Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie |
| DE60308679T2 (de) | 2002-06-11 | 2007-08-16 | Pantarhei Bioscience B.V. | Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung |
| EP1511498B1 (en) | 2002-06-11 | 2012-11-21 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| EP1526856B1 (en) | 2002-07-12 | 2008-01-02 | Pantarhei Bioscience B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
| US8987240B2 (en) | 2002-10-23 | 2015-03-24 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
| AU2003279624A1 (en) * | 2002-11-08 | 2004-06-07 | Pantarhei Bioscience B.V. | Synthesis of estetrol via estrone derived steroids |
| WO2007081206A1 (en) | 2006-01-09 | 2007-07-19 | Pantarhei Bioscience B.V. | A method of treating an acute vascular disorder |
| DE602008001783D1 (de) | 2007-01-08 | 2010-08-26 | Pantarhei Bioscience Bv | Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| ES2631359T3 (es) | 2011-08-11 | 2017-08-30 | Estetra S.P.R.L. | Uso del estetrol como anticonceptivo de emergencia |
| HRP20161282T1 (hr) | 2011-10-07 | 2016-11-18 | Estetra S.P.R.L. | Postupak za proizvodnju estetrola |
| EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
| US9988417B2 (en) * | 2013-09-18 | 2018-06-05 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
| JP6447931B2 (ja) | 2013-12-12 | 2019-01-09 | ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． | エステトロール成分を含有する口腔内崩壊固体単位剤形 |
| JP6813150B2 (ja) | 2015-06-18 | 2021-01-13 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | エステトロールを含有する口腔内崩壊錠 |
| PL3310345T3 (pl) | 2015-06-18 | 2021-10-18 | Estetra Sprl | Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol |
| LT3701944T (lt) | 2015-06-18 | 2022-04-11 | Estetra Srl | Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| JP2018533542A (ja) | 2016-10-28 | 2018-11-15 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 月経困難症および月経痛の管理のための方法 |
| ES2906380T3 (es) | 2017-08-01 | 2022-04-18 | Fund Sa | Terapia adyuvante para usar en el tratamiento del cáncer de próstata |
| CA3178181A1 (en) | 2018-02-07 | 2019-08-15 | Estetra Srl | Contraceptive composition with reduced cardiovascular effects |
| BR112022005359A2 (pt) * | 2019-09-27 | 2022-07-19 | Ind Chimica Srl | Processo de preparação de (15a,16a,17ss)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol(estetrol) e intermediários do referido processo |
-
2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
-
2020
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
- 2020-09-02 GE GEAP202015920A patent/GEP20247626B/en unknown
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 CA CA3147815A patent/CA3147815C/en active Active
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 KR KR1020227010919A patent/KR102871606B1/ko active Active
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 NZ NZ786568A patent/NZ786568A/en unknown
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 MY MYPI2022000866A patent/MY206905A/en unknown
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/en active Active
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/en not_active Ceased
-
2022
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
- 2022-09-02 PH PH1/2022/550388A patent/PH12022550388A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24692B1 (es) | Proceso industrial para la preparación de estetrol de alta pureza | |
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| ECSP19000185A (es) | Método para producir derivado de difenilmetano | |
| UY35975A (es) | Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia | |
| MY172391A (en) | Processes for preparing dihydropyrimidine derivatives and intermediates thereof | |
| UY29549A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
| UY31367A1 (es) | Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica | |
| MX378999B (es) | Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). | |
| HN2001000110A (es) | 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis | |
| UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
| CL2022000904A1 (es) | Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814). | |
| MX2016013425A (es) | Triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana, sustituidos en la posicion 3 con un anillo no aromatico que lleva un sustituyente haloalquilo. | |
| MX377644B (es) | 6.7.beta-epóxidos esteroideos como intermedios químicos. | |
| AR086987A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| UY30851A1 (es) | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos | |
| BR112019002432A2 (pt) | cristalização de glicosídeos de esteviol | |
| BR112017017066A2 (pt) | método de preparação para praziquantel e compostos intermediários do mesmo | |
| CU20200047A7 (es) | Compuestos de alquinileno sustituidos como agentes anticancerígenos | |
| CO2024009342A2 (es) | Sal derivada de triazolona como inhibidor de elastasa de neutrófilos | |
| PH12021550022A1 (en) | Spirobiindane derivatives and a process for preparation thereof | |
| MX2021009584A (es) | Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih). | |
| BR112021022347A8 (pt) | Processos e intermediários para a preparação de um inibidor de btk | |
| BR112021020864A2 (pt) | Formas cristalinas e métodos de produção de formas cristalinas de um composto | |
| PH12021552580A1 (en) | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives | |
| PL404924A1 (pl) | Nowe borany jodoniowe, sposoby ich wytwarzania i zastosowanie oraz nowe związki pośrednie |